OncoSec Medical, Inc. (OTCQB: ONCS) is a biopharmaceutical company developing its investigational ImmunoPulse intramoral cancer immunotherapy. The company’s core technology is designed to enhance local delivery and uptake of DNA-based immune-targeting agents. The lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase II development. The company also continues to focus on identifying and developing new immune-targeting agents and evaluating combination-based immunotherapy approaches. For more information, visit the company’s website at www.oncosec.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.